GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sunho Biologics Inc (HKSE:02898) » Definitions » Altman Z-Score

Sunho Biologics (HKSE:02898) Altman Z-Score : -2.82 (As of Mar. 29, 2025)


View and export this data going back to 2024. Start your Free Trial

What is Sunho Biologics Altman Z-Score?

The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.

Sunho Biologics has a Altman Z-Score of -2.82, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.

The zones of discrimination were as such:

When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.

The historical rank and industry rank for Sunho Biologics's Altman Z-Score or its related term are showing as below:


Sunho Biologics Altman Z-Score Historical Data

The historical data trend for Sunho Biologics's Altman Z-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sunho Biologics Altman Z-Score Chart

Sunho Biologics Annual Data
Trend Dec22 Dec23
Altman Z-Score
- -

Sunho Biologics Semi-Annual Data
Dec22 Jun23 Dec23 Jun24
Altman Z-Score - - - -

Competitive Comparison of Sunho Biologics's Altman Z-Score

For the Biotechnology subindustry, Sunho Biologics's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sunho Biologics's Altman Z-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sunho Biologics's Altman Z-Score distribution charts can be found below:

* The bar in red indicates where Sunho Biologics's Altman Z-Score falls into.


;
;

Sunho Biologics Altman Z-Score Calculation

Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

Sunho Biologics's Altman Z-Score for today is calculated with this formula:

Z=1.2*X1+1.4*X2+3.3*X3+0.6*X4+1.0*X5
=1.2*-0.5527+1.4*-1.1297+3.3*-0.4545+0.6*1.5465+1.0*0.0007
=-2.82

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.

Trailing Twelve Months (TTM) ended in Dec. 2023:
Total Assets was HK$317.69 Mil.
Total Current Assets was HK$248.44 Mil.
Total Current Liabilities was HK$424.02 Mil.
Retained Earnings was HK$-358.89 Mil.
Pre-Tax Income was HK$-145.15 Mil.
Interest Expense was HK$-0.76 Mil.
Revenue was HK$0.23 Mil.
Market Cap (Today) was HK$667.40 Mil.
Total Liabilities was HK$431.56 Mil.

* Note that for stock reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data.

X1=Working Capital/Total Assets
=(Total Current Assets - Total Current Liabilities)/Total Assets
=(248.442 - 424.018)/317.688
=-0.5527

X2=Retained Earnings/Total Assets
=-358.886/317.688
=-1.1297

X3=Earnings Before Interest and Taxes/Total Assets
=(Pre-Tax Income - Interest Expense)/Total Assets
=(-145.146 - -0.757)/317.688
=-0.4545

X4=Market Value Equity/Book Value of Total Liabilities
=Market Cap/Total Liabilities
=667.401/431.56
=1.5465

X5=Revenue/Total Assets
=0.228/317.688
=0.0007

The zones of discrimination were as such:

Distress Zones - 1.81 < Grey Zones < 2.99 - Safe Zones

Sunho Biologics has a Altman Z-Score of -2.82 indicating it is in Distress Zones.

Study by Altman found that companies that are in Distress Zone have more than 80% of chances of bankruptcy in two years.


Sunho Biologics  (HKSE:02898) Altman Z-Score Explanation

X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.

X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.

X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.

X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.

X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.

Read more about Altman Z-Score and the original research.


Be Aware

Altman Z-Score does not apply to financial companies.


Sunho Biologics Altman Z-Score Related Terms

Thank you for viewing the detailed overview of Sunho Biologics's Altman Z-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Sunho Biologics Business Description

Traded in Other Exchanges
N/A
Address
No. 198 Peninsula Middle Road, Dipu Street, Room 302, Building 3, Anji County, Zhejiang Province, Huzhou, CHN
Sunho Biologics Inc is a clinical-stage biopharmaceutical company that focuses on the discovery, development and commercialization of biologics for the treatment of cancers and autoimmune diseases. It has three Core Products, IAH0968, IAP0971, and IAE0972, all of which are developed in-house. IAH0968 is an antibody-dependent cell-mediated cytotoxicity (ADCC) enhanced monoclonal antibody (mAb), and the company has initiated Phase II clinical trials for biliary tract carcinoma (BTC) and colorectal cancer (CRC). IAP0971 and IAE0972 are both immunocytokines and It has completed Phase I clinical trials for advanced solid tumors including non-small cell lung cancer (NSCLC) and CRC.
Executives
Sunho Fortune Investments Limited 2201 Interest of corporation controlled by you
Trident Trust Company (hk) Limited 2301 Trustee
Zhang Feng 2201 Interest of corporation controlled by you
Sunho Wisdom Investments Limited 2101 Beneficial owner

Sunho Biologics Headlines

No Headlines